Short answer
Health Catalyst, Inc. (HCAT) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 1.02 (Termination of a Material Definitive Agreement), Item 2.01 (Completion of Acquisition or Disposition of Assets), Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). VitalWare disposition closed, transferring the business to a buyer.
Health Catalyst, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.02 · Termination of a Material Definitive Agreement
- VitalWare disposition closed, transferring the business to a buyer
- Health Catalyst providing transition services for up to six months post-closing
- Purchase Agreement governs transaction terms; filed as Exhibit 2.1 on June 4, 2026
Item 2.01 · Completion of Acquisition or Disposition of Assets
- Vitalware Disposition completed August 6, 2026, marking Health Catalyst’s exit from the disposed business
- Unit Purchase Agreement with Med-Metrix dated June 4, 2026 governs transaction terms
- Pro forma balance sheet provided as of June 30, 2026
- Pro forma operating results cover six months ended June 30, 2026 and year ended December 31, 2025
- Pro forma figures are illustrative and may not represent future consolidated financial performance
Item 2.02 · Results of Operations and Financial Condition
- Health Catalyst reported financial results for the quarter ended June 30, 2026
- Full results and management commentary available in Exhibit 99.1
- Disclosure furnished under Item 2.02, limiting Section 18 liability and incorporation by reference
Item 7.01 · Regulation FD Disclosure
- Health Catalyst completed the Disposition with the Buyer on August 6, 2026
- Transaction announcement press release attached as Exhibit 99.2
- Completion may affect Health Catalyst’s portfolio, operations, and future financial profile
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $70.5M, down 13% YoY, reflecting continued contraction despite exceeding company guidance
- Adjusted EBITDA $9.9M, up 6% YoY, while GAAP net loss remained severe at $40.5M
- Adjusted gross margin improved to 51% from 50%, led by professional services margin rising to 22% from 18%
- Cash and equivalents $60.6M plus short-term investments $42.9M, with $151.9M long-term debt still reported
- Q3 guidance: revenue $55M-$56M and Adjusted EBITDA $0-$0.5M; full-year revenue $246M-$249M and EBITDA $18M-$18.5M
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Health Catalyst, Inc. 8-K filings
Get the next HCAT 8-K as it lands
Follow HCAT for push alerts, or ask the research agent what this filing means.